Aromatic sulfone hydroxamates and their use as protease inhibitors

US6689794B2 · kind B2 · utility

Assignee

• Pharmacia Corporation · SE

Inventors

• John N. Freskos · Clayton, US
• Yvette M. Fobian · Labadie, US
• Thomas E. Barta · Evanston, US
• Daniel P. Becker · Glenview, US
• Louis Bedell · Rantoul, US
• Terri Boehm · Ballwin, US
• Jeffery Carroll · Columbia, US
• Gary A. DeCrescenzo · Holden, US
• Susan L. Hockerman · Kirkwood, US
• Darren Kassab · Wildwood, US
• Steve Kolodziej · Ballwin, US
• Joseph McDonald · Ballwin, US
• Deborah A. Mischke · Defiance, US
• Monica B. Norton · Chesterfield, US
• Joseph G. Rico · Ballwin, US
• John J. Talley · Chesterfield, US
• Clara I. Villamil · Glenview, US
• Lijuan Wang · Wildwood, US

Key dates

• Filing date: May 10, 2002
• Grant date: Feb 10, 2004
• Expiry date: Jun 30, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.